Perioperative risks of bevacizumab and other biologic agents for hepatectomy: Theoretical or evidence based?

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1786-1788

  Bilchik, Anton J ^a   Randolph Hecht, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

BIOLOGICAL THERAPY; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG POTENTIATION; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; WOUND HEALING IMPAIRMENT; ADJUVANT CHEMOTHERAPY; ANIMAL; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; LIVER TUMOR; METASTASIS; METHODOLOGY; MOUSE; NOTE; PATHOLOGY; PERIOPERATIVE PERIOD; PREMEDICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HEPATECTOMY; LIVER NEOPLASMS; LIVER REGENERATION; MICE; PERIOPERATIVE CARE; PREMEDICATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42949135561     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.6380     Document Type: Editorial

References (22)

1. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759-766, 2002
2. Kemeny N: Presurgical chemotherapy in patients being considered for liver resection. Oncologist 12:825-839, 2007
3. Fernandez FG, Drebin JA, Linehan DC, et al: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 flurodeoxyglucose (FDG-PET). Ann Surg 240:438-447, 2004
4. Abdalla EK, Curley SA, Vauthey JN, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ ablation for colorectal liver metastases. Ann Surg 239:818-827, 2004
5. Bismuth H, Adam R, Levi F, et al: Resection of unresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 66:611-615, 2000
6. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644-657, 2004
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:16s, 2005 (suppl; abstr 2)
9. Jonker DJ, Karapetis CS, Moore M, et al: Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Proceeding AACR 2007
10. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
11. Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 25:18s, 2007 (suppl; abstr 4000)
12. Nordlinger B, Sorbye H, Debois M, et al: Feasibility and risks of preoperative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM): Interim results of the EORTC Intergroup randomized phase III study 40983. J Clin Oncol 23:16s, 2005 (suppl 16; abstr 3528)
13. Bilchik AJ, Poston G, Curley SA, et al: Neoadjuvant chemotherapy for metastatic colon cancer: A cautionary note. J Clin Oncol 23:9073-9078, 2005
14. Roman CD, Choy H, Nanney L, et al: Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 105:43-47, 2002
15. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
16. Van Buren G, Yang A, Dallas N, et al: The effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 26:1836-1842, 2008
17. Gruenberger B, Tamandl D, Schueller, et al: Perioperative bevacizumab plus capecitabine and oxaliplatin does not increase surgical complications after resection of colorectal cancer liver metastases. J Clin Oncol 26:1830-1835, 2008
18. D'Angelica M, Kornprat P, Gonen M, et al: Lack of evidence after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Onc 14:759-765, 2007
19. Reddy, SK, Morse, MA, Hurwitz, HI, et al: Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg, 206: 96-106, 2008
20. Reference deleted.
21. Berry S, Cunningham D, Michael M, et al: Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and fluoropyrimidines for mCRC: First BEAT. Eur J Cancer Suppl 5:241, 2007
22. Saltz LB, Rosen LS, Marshall JL, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799, 2007